Can a new drug shrink Hard-to-Treat childhood cancers?

NCT ID NCT07734116

Not yet recruiting Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is testing an experimental drug called ONO-4538HSC (nivolumab) in children with advanced solid tumors that have not responded to standard treatments, and in patients with epithelioid sarcoma. The goal is to see if the drug is safe, tolerable, and effective at shrinking tumors. Participants receive the drug as an injection under the skin every four weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called ONO-4538HSC (nivolumab)
What this could lead to: If effective, this could offer a new treatment option for children with hard-to-treat solid tumors and for epithelioid sarcoma.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIOID SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm epithelioid sarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEDIATRIC MALIGNANT SOLID TUMOR AND EPITHELIOID SARCOMA

Contacts and locations

Locations

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan
Osaka International Cancer Institute

Osaka, Osaka, Japan
Yokohama City University Hospital

Yokohama, Kanagawa, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.